Search Results
Nov 19, 2025, 15:47 ET Die Biokonjugat-Anlage von Piramal Pharma Solutions in Grangemouth, Großbritannien, erhält aktualisierte MHRA-GMP-Zertifikate
Zulassungsanträge seiner Kunden zu unterstützen. Als spezielle Entwicklungs- und Produktionsstätte für Antikörper-Wirkstoff-Konjugate (ADC) von Piramal Pharma Solutions bietet Grangemouth umfassende Lösungen für Biokonjugate, von der Prozessentwicklung bis zur Skalierung. Der Standort spielt
More news about: Piramal Pharma Solutions
Nov 19, 2025, 15:44 ET Lo stabilimento di bioconiugati di Piramal Pharma Solutions a Grangemouth, nel Regno Unito, riceve i certificati GMP MHRA aggiornati
normative dei propri clienti. In qualità di stabilimento dedicato allo sviluppo e alla produzione di coniugati farmaco-anticorpo (ADC) di Piramal Pharma Solutions, Grangemouth offre soluzioni complete per i bioconiugati, dallo sviluppo del processo all'aumento di scala. Il sito svolge
More news about: Piramal Pharma Solutions
Nov 19, 2025, 02:48 ET Piramal Pharma Solutions' Bioconjugates Facility in Grangemouth, UK Receives Updated MHRA GMP Certificates
well-equipped to support its clients' programs and regulatory filings. As Piramal Pharma Solutions' dedicated antibody-drug conjugate (ADC) development and manufacturing facility, Grangemouth offers comprehensive solutions for bioconjugates, from process development to scale-up. The site
More news about: Piramal Pharma Solutions
Nov 19, 2025, 02:41 ET Piramal Pharma Solutions' Bioconjugates Facility in Grangemouth, UK Receives Updated MHRA GMP Certificates
well-equipped to support its clients' programs and regulatory filings. As Piramal Pharma Solutions' dedicated antibody-drug conjugate (ADC) development and manufacturing facility, Grangemouth offers comprehensive solutions for bioconjugates, from process development to scale-up. The site
More news about: Piramal Pharma Solutions
Nov 18, 2025, 08:43 ET 味之素生物製藥服務公司在 2025 World ADC Awards 中，榮獲 AJICAP® Technology 的「Best ADC Preclinical Publication 2024」殊榮
味之素株式會社企業執行董事、生物製藥服務部總經理大竹康之表示：「我們真的很榮幸獲得來自世界 ADC 社區的這一認可，」我們的 AJICAP® 技術體現了我們致力於賦能合作夥伴，將創新性抗體藥物偶聯物療法帶給我們共同服務的病人群體。」 由 Hanson Wade 主辦的 World ADC Awards，旨在表彰 ADC 藥物從發現、開發到製造過程中展現的科學與營運卓越成就。味之素生物製藥服務公司入圍 AJICAP® 「最佳抗體藥物偶聯物平台技術」(Best ADC Platform Technology) 類別，並榮獲出版獎項殊榮。獲獎者由一個獨立評審團選出，該評審團由 ADC 範疇的專家和來自全球生物製藥界的同行組成。
More news about: Ajinomoto Bio-Pharma Services
Nov 18, 2025, 08:38 ET 味の素バイオファーマサービス、AJICAP®技術に関する論文で「Best ADC Preclinical Publication 2024」受賞 ～2025年World ADC Awards
2025年11月18日 /PRNewswire/ -- 味の素バイオファーマサービス（Ajinomoto Bio-Pharma Services、以下「Aji Bio-Pharma」）は本日、同社のAJICAP®リンカー技術に関する研究論文が評価され、第12回World ADC Awardsにおいて「Best ADC Preclinical Publication 2024」を受賞したと発表しました。この受賞は、バイオ医薬品の開発・製造受託サービスを提供するリーディングカンパニーとして同社が示す革新的な研究成果を高く評価するものです。
More news about: Ajinomoto Bio-Pharma Services
Nov 18, 2025, 08:31 ET 아지노모토 바이오파마 서비스, 2025 월드 ADC 어워드에서 AJICAP® 기술로 '2024년 최우수 ADC 전임상 논문' 수상 쾌거
Otake)는 "월드 ADC 어워드 주최 측의 인정을 받게 되어 영광"이라고 전하면서 "AJICAP® 기술은 파트너와 힘을 모아 혁신적인 ADC 치료제를 환자들에게 전하려는 아지노모토의 의지로 점철된 결정체이기도 하다"라고 강조했다. 핸슨 웨이드(Hanson Wade)가 주최하는 월드 ADC 어워드는 ADC 발굴, 개발, 제조 분야의 뛰어난 과학적 성과와 운영 능력을 기리는 시상식이다. 아지 바이오파마는 AJICAP® 기술로 '최우수 ADC 플랫폼 기술(Best
More news about: Ajinomoto Bio-Pharma Services
Nov 17, 2025, 09:12 ET Ajinomoto Bio-Pharma Services Wins "Best ADC Preclinical Publication 2024" Award for AJICAP® Technology at 2025 World ADC Awards
collectively serve." The World ADC Awards, organized by Hanson Wade, celebrate scientific and operational excellence across ADC discovery, development, and manufacturing. Aji Bio-Pharma was shortlisted for AJICAP® in the "Best ADC Platform Technology" category and was further
More news about: Ajinomoto Bio-Pharma Services
Nov 17, 2025, 08:59 ET Ajinomoto Bio-Pharma Services Wins "Best ADC Preclinical Publication 2024" Award for AJICAP® Technology at 2025 World ADC Awards
collectively serve." The World ADC Awards, organized by Hanson Wade, celebrate scientific and operational excellence across ADC discovery, development, and manufacturing. Aji Bio-Pharma was shortlisted for AJICAP® in the "Best ADC Platform Technology" category and was further
More news about: Ajinomoto Bio-Pharma Services
Nov 14, 2025, 07:00 ET TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
relapsed or refractory NPM1-mutated AML in combination with a menin inhibitor. Lead ADC Selection Q1 2026: TuHURA has developed a
More news about: TuHURA Biosciences, Inc.
Nov 13, 2025, 05:00 ET Yatsen Group Unveils Beauty Innovation Insight, Defining the Next Era of World-Class Beauty Science
peer-reviewed format. Over the past four years, Yatsen has participated in major dermatological and cosmetic congresses, including the IFSCC, EADV, ADC, and WCD, strengthening China's scientific voice in the global beauty dialogue. From Lab to Market: Turning
More news about: Yatsen Holding Limited
Nov 11, 2025, 08:00 ET Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London
an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that Dave Lennon, PhD, President and CEO, will present at the Jefferies Global Healthcare Conference in London on
More news about: Whitehawk Therapeutics, Inc.
Nov 11, 2025, 02:34 ET Guo Guangchang: Fosun Strengthens Globalization Capabilities, Accelerates Innovation through Open Cooperation
HLX43, a PD-L1-targeting antibody-drug conjugate (ADC) is undergoing clinical studies for solid tumors such as non-small cell lung cancer and thymic carcinoma in countries including China, the United States, Japan, and Australia. Currently, no PD-L1 ADC has been approved globally, positioning HLX43 as
More news about: Fosun
Nov 10, 2025, 17:31 ET Oropharyngeal Cancer Market to Register Steady CAGR Throughout Forecast Period (2025-2034) Amid Shifting Treatment Paradigms | DelveInsight
settings. The Versamune HPV platforms, both the doublet (Versamune HPV + KEYTRUDA) and the triplet (Versamune HPV + PDS01ADC + Bintrafusp alfa) regimens, have demonstrated sustained efficacy and are anticipated to influence the treatment landscape for HPV16-positive HNSCC significantly.
More news about: DelveInsight Business Research, LLP
Nov 10, 2025, 07:30 ET ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update
for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early-stage PSMA-targeting ADC. ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment
More news about: ADC Therapeutics SA
Nov 09, 2025, 20:55 ET Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress
projects are in the clinical stage. The company has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 07, 2025, 09:00 ET Marengo Late-Breaking Oral Presentation Highlights Single-Agent, Pan Tumor Activity of Invikafusp Alfa Across PD-1-Resistant Cancers in Phase 2 Clinical Trial at SITC 2025
with Trodelvy® (a TROP2-directed antibody-drug conjugate) in triple-negative breast cancer (TNBC) and HR⁺/HER2⁻ breast cancer to evaluate synergy in ADC + IO combination settings. In parallel, Marengo continues to advance regulatory interactions, including recent receipt of U.S. FDA Fast Track designation
More news about: Marengo Therapeutics
Nov 07, 2025, 06:12 ET October in Review: 10 Top Health Press Releases
to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market The collaboration combines Innovent's proven immuno-oncology ("IO") and antibody-drug conjugate ("ADC") R&D capability and Takeda's experience in global
More news about: PR Newswire
Nov 06, 2025, 20:00 ET Fosun International Honored with Gold Award and Best Sustainability Team at The Asset Corporate Sustainability Leadership Awards 2025
HLX43, a PD-L1-targeting antibody-drug conjugate (ADC) is undergoing clinical studies for solid tumors such as non-small cell lung cancer and thymic carcinoma in countries including China, the United States, Japan, and Australia. Currently, no PD-L1 ADC has been approved globally, positioning HLX43 as
More news about: Fosun
Nov 06, 2025, 17:31 ET Endometrial Cancer Market Poised for Expansion Throughout Forecast Period (2025-2034) Amid Increasing Adoption of Immunotherapies | DelveInsight
conjugated to a topoisomerase I inhibitor. As a third-generation Antibody-Drug Conjugate (ADC), it specifically targets TROP2-expressing cells. The drug is administered intravenously in powder form and utilizes advanced ADC conjugation technology. It is currently in development for the treatment of endometrial
More news about: DelveInsight Business Research, LLP
Nov 06, 2025, 11:05 ET 再鼎醫藥公布 2025年第三季度財務業績和近期公司進展
ocilurtatug P elitecan ( zoci, DLL3 ADC) （前稱 ZL-1310 ） :
More news about: 再鼎醫藥
Nov 06, 2025, 08:00 ET Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
AACR-NCI-EORTC. Confirming PTK7 as the third most highly expressed tumor marker among clinically validated and emerging ADC targets, these data underscore the tremendous opportunity we have with our first ADC candidate, HWK-007, to make a difference for the nearly 750,000 patients in the US with PTK7-expressing cancers."
More news about: Whitehawk Therapeutics, Inc.
Nov 06, 2025, 04:46 ET WuXi XDC Named the Winner of "Best CDMO" and "Best CRO" at 2025 World ADC Awards
As one of the most influential annual awards in the global ADC sector, the World ADC Awards honor companies, teams and innovations that have made outstanding contributions to the field. This year's World ADC Conference brought together global experts, scholars, and industry leaders to
More news about: WuXi XDC
Nov 05, 2025, 17:31 ET Rheumatoid Arthritis Market to Surge by 2034 as Next-Generation Biologics and JAK Inhibitors Gain Traction | DelveInsight
In October 2025, Lifordi Immunotherapeutics, Inc. shared preclinical findings for its lead candidate, LFD-200, an ADC designed to deliver a potent glucocorticoid (GC) specifically to immune cells. The company also reported that its Phase 1 clinical trial of LFD-200 for
More news about: DelveInsight Business Research, LLP
Nov 05, 2025, 16:15 ET Kestrel Group Reports Third Quarter 2025 Financial Results
business as well as a reduction of $3.6 million in the amount recoverable under the Loss Portfolio Transfer and Adverse Development Cover Agreement ("LPT/ADC Agreement"). These amounts were offset by favorable development in Workers' Compensation and other lines of business. The segment's Diversified business
More news about: Kestrel Group Ltd